TISIDB

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum
Domain	PF02214 BTB/POZ domain
Function	Inhibits potassium fluxes in cells. May regulate Kv1 family channel proteins by retaining a fraction of channels in endomembranes.

> Gene Ontology [ TOP ]
Biological Process	GO:0006813 potassium ion transport GO:0010959 regulation of metal ion transport GO:0015672 monovalent inorganic cation transport GO:0022898 regulation of transmembrane transporter activity GO:0032409 regulation of transporter activity GO:0032410 negative regulation of transporter activity GO:0032412 regulation of ion transmembrane transporter activity GO:0032413 negative regulation of ion transmembrane transporter activity GO:0034762 regulation of transmembrane transport GO:0034763 negative regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0034766 negative regulation of ion transmembrane transport GO:0043266 regulation of potassium ion transport GO:0043267 negative regulation of potassium ion transport GO:0043271 negative regulation of ion transport GO:0051051 negative regulation of transport GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0071804 cellular potassium ion transport GO:0071805 potassium ion transmembrane transport GO:1901016 regulation of potassium ion transmembrane transporter activity GO:1901017 negative regulation of potassium ion transmembrane transporter activity GO:1901379 regulation of potassium ion transmembrane transport GO:1901380 negative regulation of potassium ion transmembrane transport GO:1902259 regulation of delayed rectifier potassium channel activity GO:1902260 negative regulation of delayed rectifier potassium channel activity GO:1903817 negative regulation of voltage-gated potassium channel activity GO:1904062 regulation of cation transmembrane transport GO:1904063 negative regulation of cation transmembrane transport GO:2001257 regulation of cation channel activity GO:2001258 negative regulation of cation channel activity
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KCNRG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KCNRG in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.75	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KCNRG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.109	0.553
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.089	0.809
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.122	0.687
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.512	0.504
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.039	0.983
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.208	0.596
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.186	0.658
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.118	0.876
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.288	0.716
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.481	0.324
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.481	0.496
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.354	0.00796

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KCNRG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCNRG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCNRG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCNRG. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCNRG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KCNRG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KCNRG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KCNRG
Name	potassium channel regulator
Aliases	DLTET; putative potassium channel regulatory protein; Protein CLLD4; Potassium channel regulatory protein
Chromosomal Location	13q14.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KCNRG collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KCNRG